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 The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are 
generally well tolerated as monotherapy. Statins are associated with two important adverse 
effects, asymptomatic elevation in liver enzymes and myopathy. Myopathy is most likely to 
occur when statins are administered with other drugs. Statins are substrates of multiple drug 
transporters (including OAT- -P1B1, BCRP and MDR1) and several cytochrome P450 (CYP) 
enzymes (including CYP3A4, CYP2C8, CYP2C19, and CYP2C9). Possible adverse effects 
of statins can occur due to interactions in concomitant use of drugs that substantially inhibit 
or induce their methabolic pathway. This review aim is to summarize the most important 
interactions of statins. 
Please cite this article in press as Mr. A. Satish Chandra et al. A Review on Pharmaco Kinetic Drug Interactions of Statins. Indo 
American Journal of Pharmaceutical Research.2017:7(01). 
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INTRODUCTION 
Statins (or HMG-CoA reductase inhibitors) represent a class of drugs used to lower cholesterol levels by inhibiting the 
enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. As of 2010, a number of statins 
have been on the market: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin  Statins are 
associated with two uncommon, but important, adverse effects, asymptomatic elevation in liver enzyme activity and myopathy. (1, 2). 
At the pharmacodynamic level (i.e., at their site of action), statins are not prone to interfere with other drugs. However, at the 
pharmacokinetic level (i.e., absorption, distribution, metabolism and excretion of a given drug), the available statins show notable 
differences, including half-life, systemic exposure, maximum plasma concentration (Cmax), bioavailability, protein binding, 
lipophilicity, metabolism, presence of active metabolites, and excretion routes that is explained below with examples for mechanism 
of drug inter actions. 
 
Mechanisms 
There are several mechanisms by which drugs may interact (3-5), and most of these mechanisms can be categorized as 
pharmacokinetic (involving intestinal absorption, distribution, metabolism, and elimination) or as pharmacodynamic, or as additive 
toxicity, respectively. Pharmacokinetic interactions: the interaction in intestinal absorption is best illustrated by an example: 
tetracylines and other broad-spectrum antibiotics may impair the absorption of oral contraceptives (in particular those with low-dose 
progestogens and/or estrogens) and hence render contraception unsafe. Several drugs are subject to inactivation via metabolic 
degradation it the liver, catalysed by various liver enzymes.  
The formation of these enzymes can be induced or enhanced by drugs such as rifampicine, griseofulvine, and several anti-
epileptics (carbamazepin, phenytoine, phenobarbital), but also by regular alcohol consumption. 
This process, which requires several weeks of treatment and which is indicated as enzyme induction, enhances the metabolic 
degradation of several drugs.  
In practice, enzyme induction may play a relevant role for oral anticoagulants (coumarin type), corticosteroids 
(glucocorticoids), oral contraceptives, or quinidine. Accordingly, these categories of drugs are metabolized/inactivated more rapidly 
and their doses should therefore be increased. 
A comparable but opposite problem is the inhibition of liver enzymes involved in the biotransformation by a variety of drugs, 
such as cimetidine, erythromycin, metronidazole, tricyclic antidepressants, phenothiazine-neuroleptics, and sulphonamides (also in co-
trimoxazole). Enzyme inhibitors of this type impair the biodegradation of certain drugs and hence increase their effects.  
A wellknown problem is the enhanced effect of anticoagulants (as reflected by bleeding) induced by additional treatment 
with co-trimoxazole. Certain drugs may impair the renal excretion (3-5) of other agents, usually at the renal tubular level. 
A well-known relevant example is the rise in the plasma level and toxicity of digoxin, provoked by verapamil, amiodarone, 
or quinidine. Similarly, thiazide diuretics may decelerate the renal elimination of lithium salts and hence reinforce their toxicity. A 
beneficial effect of such an interaction is the impaired excretion of penicillin antibiotics induced by simultaneously administered 
probenecide. 
Pharmacodynamic interactions and additive toxicity (3-5: Pharmacodynamic interactions between similarly acting drugs may 
lead to additive or even over-additive effects (potentiation). A well-known example is the combination of i.v. verapamil and a ß-
blocker, which may cause additive impairment of cardiac A-V conduction and the risk of A-V block. 
 Another possibility is the inhibition of the therapeutic effect of a drug by an additional agent. Over-additive adverse 
reactions are illustrated by the following example: a most important interaction, probably caused by non-specific mechanisms, is the 
mutual enhancement of the central nervous depressant effects of all drugs that are known to dampen the activity of the central nervous 
system. 
This interaction holds for hypnotics, anxiolytics (minor tranquillizers), antipsychotics (neuroleptics, major tranquillizers), 
anti-epileptics, and opioids, but also for drugs with central nervous depressant adverse reactions, such as antihistamines, centrally 
acting antitussives (codeine, etc.), and scopolamine (3-5, 6).  
Furthermore, alcohol enhances the central nervous depressant effects of all of the aforementioned therapeutics. Accordingly, 
enhanced sedation, impaired psychomotor skills (driving), but also respiratory depression may occur. The major drug interactions of 
statins tabulated  below table. 
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Interacting Drug Findings and Mechanism of Interaction Recommendations/Comments 
Amiodarone  
(e.g., Cordarone, 
generics) 
 Increased risk for myopathy/rhabdomyolysis due 
to decreased metabolism of atorvastatin, 
lovastatin, and simvastatin. 
 Amiodarone is a CYP3A4 and CYP2C9 
(moderate) inhibitor(.2) 
1. Do not exceed 40 mg 
lovastatin or 20 mg 
simvastatin.
7,9,11
 
2. Consider limiting atorvastatin 
dose.
11
  
3. Fluvastatin is primarily 
metabolized bycyp3a4 
 
Azole 
 Antifungals 
Fluconazole (Diflucan, 
generics) Itraconazole 
(Sporanox) 
Ketoconazole (Nizoral, 
generics) Posaconazole 
(Noxafil [U.S.], 
Posanol [Canada]) 
Voriconazole (Vfend) 
 Increased risk for myopathy/rhabdomyolysis due 
to decreased metabolism of atorvastatin, 
fluvastatin, lovastatin, and simvastatin. 
 Itraconazole, ketoconazole, posaconazole, and 
voriconazole are strong CYP3A4 inhibitors.64  
  Fluconazole is a moderate CYP3A4 and 
CYP2C9 inhibitor.64 
1. Hold lovastatin and simvastatin 
during the course of itraconazole, 
ketoconazole, or posaconazole 
treatment.
7,9
 
2. Consider reduced lovastatin or 
simvastatin dose when used with 
voriconazole.
7,9,16
  
3. Hold atorvastatin during the course 
of itraconazole treatment.
25 
 
4. Consider reduced atorvastatin dose 
if used with ketoconazole, 
posaconazole, or voriconazole.
26
 
5. Use caution when coadministering 
fluconazole with atorvastatin, 
lovastatin, simvastatin, or 
fluvastatin.
18,19
 
6. Fifty percent statin dose reduction 
suggested.18 Limit fluvastatin 
dose to 20 mg twice daily.
21 
 
7.  Consider fluvastatin, rosuvastatin, 
or pravastatin rather than 
lovastatin, simvastatin, or 
atorvastatin with itraconazole or 
ketoconazole.
30,31
 
Bile Acid Sequestrants 
Cholestyramine (e.g., 
Prevalite [U.S.]. 
 Olestyr [Canada], 
generics) Colestipol 
(Colestid, generics 
[U.S.]) 
Decreased bioavailability of statins due to the drugs 
binding in the intestine. 
1. Administer statins 1 hr before or at 
least 4 hrs after cholestyramine or 
colestipol.
25-27
 
2. Some Canadian statin monographs 
(atorvastatin, lovastatin, and 
simvastatin) recommend at least 2 
hours elapse between statin 
administration and administration 
of bile acid sequestrants.
12,14,24
 
Calcium Channel 
Blockers 
(Amlodipine, 
Diltiazem, Verapamil) 
Amlodipine: Increased risk for 
myopathy/rhabdomyolysis due to 
decreased metabolism of simvastatin 
1. Do not exceed lovastatin 20 mg or 
2. simvastatin 10 mg with verapamil 
ordiltiazem.
11,13
 
Grapefruit/Grapefruit 
Juice 
 
 
 
Increased risk formyopathy/rhabdomyolysis due 
todecreased metabolism of atorvastatin,lovastatin, and 
simvastatin. 
Grapefruit juice inhibits CYP3A4 and Pglycoprotein. 
 
1. Experts suggest avoiding 
grapefruit withatorvastatin, 
simvastatin, and lovastatin.
33
 
2. Consider using pravastatin, 
rosuvastatin, orfluvastatin. 
Macrolide Antibiotics 
Clarithromycin (e.g., 
Biaxin, generics) 
Erythromycin 
Increased risk for 
myopathy/rhabdomyolysis due to 
decreased metabolism of atorvastatin, 
lovastatin, and simvastatin. 
These macrolides are CYP3A4 
inhibitors.64 
1. Lovastatin and simvastatin should 
be 
heldduringtreatmentwiththesemacr
olides
.11,13
 
2. Do not exceed atorvastatin 20 
mgwith clarithromycin. Also 
consider cautiousdosing with 
erythromycin.
24
 
3. Use azithromycin if treatment 
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withamacrolideantibioticisunavoid
able. 
4. Do not exceed pravastatin 40 mg 
withclarithromycin.
29
 
5. Use rosuvastatin or fluvastatin 
inpatientswho require frequent 
orprolonged treatmentwith 
clarithromycin or erythromycin. 
6. • Limit pitavastatin to 1 mg 
witherythromycin. 
Warfarin Potential increase in INR due to decreased 
warfarin metabolism and displacement of 
warfarin from protein binding sites. 
1. Monitor INR closely when 
initiating,stopping, or changing the 
statin dos  
2. Atorvastatin may be less likely to 
interact.
24,29
 
 
 
CONCLUSION  
Statins have proven to be safe in numerous clinical trials. However, studies have shown that they can interact with other co-
administered medicines. The different pharmacokinetic profiles of different statins should be carefully examined in order to 
understand the different spectra of drug interactions. These interactions are important determinants of safety in patients with 
hypercholesterolemia, especially those requiring long-term therapy with drugs that are well-known CYP3A4 inhibitors/inducers 
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